Research-framed writing on the compounds we stock, the methodology we apply, and the regulatory landscape we operate under. Written for lab-facing readers. No therapeutic language, no supplement framing, no consumption guidance.
A structured index of the peer-reviewed preclinical research in which BPC-157 has appeared as a study compound or reference reagent — grouped by model system, methodology, and citation density. Built as a bibliographic tool, not a therapeutic narrative. Last refreshed against PubMed on 14 April 2026.
Read the index →A survey of the peer-reviewed wound-healing and fibroblast-migration studies in which Thymosin Beta-4 fragment TB-500 has appeared as a reagent or comparator compound.
What the 214 nm UV trace actually tells a researcher about a lyophilised peptide sample — peak area, retention reproducibility, and the anatomy of a false ≥99% claim.
The primary sources. Which compounds are controlled, which are regulated as medicines, and which sit in the research-reagent space — quoted directly from the MHRA guidance documents.
A layered walk through where the vast majority of UK and EU peptide stock actually originates — bulk synthesis partners, relabelling economics, and why the provenance receipt matters.
Storage temperature, freeze-thaw cycling, and post-reconstitution stability — a plain-English methodology note on how a research-grade peptide survives from synthesis to the lab bench.
Where the copper-binding tripeptide appears in fibroblast and skin-model studies, and how it is handled as a reference reagent in dermatological research assays.
A technical note on the release-testing water-content assay — why the 8% acceptance threshold matters, and what the result actually implies about a peptide's shelf stability.
An editorial on what gets lost when a research reagent is resold as a wellness product — traceability, documentation, and the erosion of the citation chain between a synthesis batch and a published paper.
A clean read of the Misuse of Drugs Act 1971 schedules as they relate to growth hormone and its direct analogues — and why EmirG / R will not stock or supply any compound in that scope.
New compound briefs, methodology notes, and regulatory reading — mailed weekly. Written for lab-facing readers. No supplement framing, no retail promotion, no unsubscribe obstacle.